Browsing Tag
Edwards Lifesciences
5 posts
Anteris Technologies (ASX: AVR) stock up 9.6% as PARADIGM trial reaches first US patient enrolments
Edwards and Medtronic own TAVR. Anteris (ASX: AVR) wants in with DurAVR. First US PARADIGM patients enrolled, US$320m raised, and Medtronic is now a shareholder.
Medtronic invests in Anteris (ASX: AVR) to fund DurAVR trial and TAVR platform expansion
Anteris Technologies has raised USD 320M, including USD 90M from Medtronic, to fund its global DurAVR heart valve trial. Read what this means for TAVR competition.
Anteris Technologies launches its pivotal trial phase for DurAVR THV, marking a regulatory turning point
Anteris Technologies launches the global PARADIGM pivotal trial of its DurAVR THV, challenging Edwards and Medtronic with biomimetic valve durability data—see how the race unfolds.
Prompt treatment for severe aortic stenosis cuts costs, enhances outcomes, new real-world study shows
New data from over 24,000 patients shows early intervention for severe aortic stenosis slashes costs and deaths—read how timing changes patient outcomes.
BD to acquire Edwards Lifesciences’ Critical Care product group for $4.2bn
In a major strategic move, Becton, Dickinson and Company (NYSE: BDX), widely known as BD, has entered into…